Next Article in Journal
Comparison of Origanum Essential Oil Chemical Compounds and Their Antibacterial Activity against Cronobacter sakazakii
Next Article in Special Issue
Synthesis, Structure and Molecular Docking of New 4,5-Dihydrothiazole Derivatives Based on 3,5-Dimethylpyrazole and Cytisine and Salsoline Alkaloids
Previous Article in Journal
Application of Biobased Solvents in Asymmetric Catalysis
Previous Article in Special Issue
GC-MS/MS Determination of Steroid Hormones in Urine Using Solid-Phase Derivatization as an Alternative to Conventional Methods
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 19
10.3390/molecules27196700
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis, and Bioactivity Study of Novel Tryptophan Derivatives Containing Azepine and Acylhydrazone Moieties

by
Jingjing Zhang
1,2,
Rongxin Yang
2,
Lili Li
2,
Jianhua Liu
2,
Yuxiu Liu
2,
Hongjian Song
2,* and
Qingmin Wang
2,*
1
College of Basic Science, Tianjin Agricultural University, Tianjin 300384, China
2
State Key Laboratory of Elemento-Organic Chemistry, College of Chemistry, Frontiers Science Center for New Organic Matter, Nankai University, Tianjin 300071, China
*
Authors to whom correspondence should be addressed.
Molecules 2022, 27(19), 6700; https://doi.org/10.3390/molecules27196700
Submission received: 26 September 2022 / Revised: 5 October 2022 / Accepted: 6 October 2022 / Published: 8 October 2022
(This article belongs to the Special Issue Novel Natural and Derivative Products: Synthesis and Pharmacological Potential)
Browse Figures
Versions Notes

Abstract

:
Based on the scaffolds widely used in drug design, a series of novel tryptophan derivatives containing azepine and acylhydrazone moieties have been designed, synthesized, characterized, and evaluated for their biological activities. The bioassay results showed that the target compounds possessed moderate to good antiviral activities against the tobacco mosaic virus (TMV), among which compounds 5c, 6a, 6h, 6t, 6v, and 6y exhibited higher inactivation, curative, and protection activities in vivo than that of ribavirin (40 ± 1, 37 ± 1, 39 ± 2% at 500 mg/L). Especially, 6y showed comparable activities to that of ningnanmycin (57 ± 2, 55 ± 3, 58 ± 1% at 500 mg/L). Meanwhile, we were pleased to find that almost all these derivatives showed good larvicidal activities against Plutella xylostella. Meanwhile, these derivatives also showed a broad spectrum of fungicidal activities.

1. Introduction

Natural products are secondary metabolites retained by natural organisms through long-term evolution and natural selection [1]. Because natural products often have the characteristics of chemical structure and biological activity diversity, they have great value in the development and utilization of drugs [2,3,4,5].
L-Tryptophan is not only an essential amino acid that constitutes the proteins of living substance, but is also a very important structural unit in the biosynthesis of natural products [6]. Due to its multiple functional groups, such as carboxyl, amino, and indole groups, tryptophan can be modified to form a variety of different structural units. Furthermore, some tryptophan derivatives also have great value in the fields of biology and medicine [7]. Although there is a lot of research on the biological activities of tryptophan, there are few studies focused on its application in the field of pesticides. In our previous work, we found, for the first time, that tryptophan exhibits antiplant virus activity [8]. Therefore, it can be used as an antiviral lead for structural optimization.
Azepines are important structural motifs that widely exist in natural products and pharmaceuticals [9,10,11,12] (Figure 1). Due to their special structure type and electron cloud distribution, azepines have been widely used in the design of antitumor [13,14,15], antihypertension [16], anti-inflammatory [17], antibacterial, and antifungal [18] drugs.
Acylhydrazones are products obtained by combining hydrazides with ketones or aldehydes. The bioactive acylhydrazone core has been one of the most ubiquitous functional groups in medicinal chemistry, and it has been identified in a huge number of lead compounds that act on various types of molecular targets [19,20,21,22,23]. In our previous work, it was found that the introduction of acylhydrazone fragments was very beneficial to improve the antiplant virus of the compound [24,25,26].
In this work, to improve the antivirus activity of tryptophan, we designed and synthesized a series of novel tryptophan derivatives containing azepine and acylhydrazone moieties and first evaluated their biological activities (Figure 2). In addition, the larvicidal and fungicidal activities of the newly synthesized tryptophan derivatives were also studied to expand their potential agricultural applications.

2. Results

2.1. Chemistry

Tryptophan underwent esterification, sulfonylation, nucleophilic substitution, cyclization under acidic conditions, and finally, hydrazinolysis of esters (4a–4c) to obtain hydrazide compounds 5a–5c (Scheme 1). Hydrazide compounds 5a–5c reacted with 4-chlorobenzaldehyde through a condensation reaction to give 6a–6c (Scheme 2). Additionally, 6a–6aa was synthesized by the condensation reaction between 5a and corresponding aldehydes (Scheme 3).

2.2. Antiviral Activities

Using the commercial plant viricides ningnanmycin and ribavirin as controls, we first evaluated the inactivation effect of compounds 5a–5c and 6a–6aa against TMV in vivo at 500 mg/L, and then the curative and protective modes of antiviral activity were tested at both 500 and 100 mg/L for these compounds, with more than a 40% in vivo inactivation effect at 500 mg/L (Table 1). The bioassay results showed that most of these compounds were active against TMV, and some of these compounds exhibited better anti-TMV activities than ribavirin, such as hydrazide compounds (5b and 5c) and acylhydrazone compounds (6a, 6e, 6g, 6h, 6m, 6n, 6t, 6v, 6y). In particular, 5c, 6a, 6h, 6t, 6v, and 6y exhibited comparable activity with ningnanmycin.
To compare the structure–activity relationship between hydrazide and acyhydrazone compounds, we studied the anti-TMV activity of compounds 5a–5c and 6a–6c. The bioassay results showed that these two types of compounds showed different structure–activity relationships: For the hydrazide compounds 5a–5c, the effect of R1 on anti-TMV activity was shown as 4-chlorophenyl (5c) > 4-methoxyphenyl (5b) > phenyl (5a). In contrast, after the introduction of the acylhydrazone moiety, only the anti-TMV activity of 6a was improved, and the antiviral activities of the three compounds decreased in the order 6a > 6b ≈ 6c.
For these acyhydrazone compounds, when R1 was phenyl, the types of R2 and the substituents on it (R2) had important effects on the anti-TMV activity. When R2 was phenyl, the types, positions, and number of the substituents on the benzene ring had a significant effect on the anti-TMV activity of these compounds (6d–6z). Furthermore, 6a (R2 = 4-chlorophenyl), 6h (R2 = 2-methoxyphenyl), 6t (R2 = 2,3-dihydrobenzo[b][1,4]dioxin-6-yl), and 6v (R2 = 4-bromo-2,6-difluorobenzyl) exhibited higher anti-TMV activities than other compounds. The positions of these substituents on the benzene ring also affected the anti-TMV activities; moreover, the influence of the position of these substituents with different electrical properties on the activity was also different. For the electron-withdrawing group (such as chloro) on the benzene ring, the order of their activity level was para (6a) > meta (6n) > ortho (6o). However, for the electron-donating group (such as methoxy) on the benzene ring, the order of their activity level was ortho (6h) > meta (6g) > para (6f). In addition, the number of substituents on benzene rings also influenced the anti-TMV activity, whether it was for the electron-withdrawing group or the electron-donating group; the more the number of substituents on the benzene ring, the lower the anti-TMV activity of these compounds. For example, compounds 6p, 6q, and 6r showed lower anti-TMV activity than monosubstituted compounds. Noteworthily, 6t (R2 = 2,3-dihydrobenzo[b][1,4]dioxin-6-yl) showed higher activity than 6s (R2 = benzo[d][1,3]dioxo-5yl) and 6r (R2 = 3,4-dimethoxyphenyl).
When R2 was aromatic heterocyclic (6w–6y), these compounds exhibited the following structure–activity relationship: 6y (R2 = 1H-pyrrol-2yl) > 6x (R2 = thiophene-2-yl) > 6w (R2 = pyridin-3-yl).
When R2 was the aliphatic substituent (6z and 6aa), the anti-TMV activities of these two compounds were lower than that of ribavirin. This suggested that aliphatic substituents were unfavorable for improving the anti-TMV activity of these compounds.

2.3. Larvicidal Activity

In general, almost all the compounds showed larvicidal activity against Plutella xylostella, and especially, 6k, 6m, and 6z showed >80% larvicidal activities at 100 mg/L (Table 2). By comparing the larvicidal activities of hydrazide compounds 5a–5c and acylhydrazones compounds 6a–6c, the introduction of benzylidene was detrimental to the larvicidal activity. For these acyhydrazone compounds, the introduction of substituents on benzylidene had a significant effect on the larvicidal activity, and the introduction of lipophilic substituents was beneficial to the larvicidal activity, such as tert-butyl (6k) and phenyl (6m). The introduction of the heteroaromatic ring (R2) had no obvious improvement in larvicidal activity (6w–6y). For aliphatic substituents (6z and 6aa), the introduction of tert-butyl (6z) could improve the larvicidal activity of the compound (LC50 was 21.2 mg/L, Table 3). The above bioassay results showed that the introduction of lipophilic substituents was beneficial to larvicidal activity, which provided useful information for subsequent structural optimization.

2.4. Fungicidal Activities

Finally, we investigated the antiphytopathogenic activity of these compounds (Table 4). The fungicidal activities of these compounds against 14 kinds of phytopathogenic fungi were evaluated using the mycelial growth method. Most of these compounds showed fungicidal activities against 14 kinds of plant pathogens at 50 mg/L. These compounds showed selectivity against these fungi, and most compounds exhibited >60% fungicidal activity against Fusarium moniliforme at 50 mg/L. Some compounds exhibited broad-spectrum fungicidal activities; compounds 5a and 5c showed > 60% fungicidal activity against five kinds of plant pathogens at 50 mg/L, and compounds 6r and 6aa showed > 60% fungicidal activity against six kinds of plant pathogens at the same concentration. Some compounds showed excellent fungicidal activity against a certain species of fungus selectively, such as 5a, 6d, 6m, 6t, and 6w that showed 90 ± 1%, 92 ± 1%, 100%, 98 ± 1%, and 90 ± 0% inhibition rates against Rhizoctonia cerealis, respectively. In the meantime, 6t showed 94 ± 1% and 100% inhibition rates against Cercospora arachidicola Hori and Fusarium moniliforme, respectively.

3. Materials and Methods

3.1. Materials

1H, 13C nuclear magnetic resonance (NMR) spectra were obtained at 400 MHz and 100 MHz using a Bruker AC-P 400. Chemical shift values (δ) were given in parts per million (ppm) and were downfield from internal tetramethylsilane. High-resolution mass spectra (HRMS) data were obtained on an FTICR-MS instrument (Ionspec 7.0 T). The melting points were determined on an X-4 binocular microscope melting point apparatus and were uncorrected. Reaction progress was monitored via thin-layer chromatography on silica gel GF-254 with detection by UV.
Ribavirin (Topscience Co. Hongkong, China), ningnanmycin (Alta Scientific Co. Tianjin, China), chlorothalonil (Bailing Agrochemical Co. Jiangyin, China), rotenone (Accela ChemBio Inc. Shanghai, China), and other reagents were purchased from commercial sources and were used as received.

3.2. General Synthesis

The synthetic routes of target compounds 5a−5c, 6a−6aa are depicted in Scheme 1, Scheme 2 and Scheme 3 [27]. The spectra of target compounds 5a−5c, 6a−6aa are depicted in the Supplemetary Materials, Section S1: Copies of NMR spectra (Figures S1–S76).

3.2.1. Synthesis of (S)-methyl 2-amino-3-(1H-indol-3-yl)propanoate (1)

To a solution of L-tryptophan (10 g, 48.97 mmol) in anhydrous methanol (150 mL), SOCl2 (10 mL) was slowly added dropwise and then heated at 100 °C. When the reaction was complete, as indicated by thin-layer chromatography (5 h), the reaction mixture was cooled to room temperature, and then, the mixture was concentrated in vacuo and washed with the anhydrous Na2CO3 saturated solution, extracted with ethyl acetate (50 mL × 3), and the combined organic phases were washed with brine, dried over Na2SO4, and filtered; the filtrate was evaporated under reduced pressure to give a brown solid (9.71 g, 91%, mp 90–91 °C). 1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 7.02 (d, J = 2.0 Hz, 1H), 3.84 (dd, J = 7.6, 4.8 Hz, 1H), 3.71 (s, 3H), 3.28 (dd, J = 14.4, 4.8 Hz, 1H), 3.05 (dd, J = 14.4, 8.0 Hz, 1H), 1.64 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 175.8, 136.3, 127.5, 123.0, 122.2, 119.5, 118.8, 111.3, 111.0, 55.0, 52.1, 30.8.

3.2.2. Synthesis of (S)-methyl 3-(1H-indol-3-yl)-2-(4-methylphenylsulfonamido)propanoate (2)

To a mixture of 1 (8.63 g, 39.5 mmol) and NEt3 (11 mL, 79 mmol) in anhydrous dichloromethane (120 mL), para toluenesulfonyl chloride (7.69 g, 59.3 mmol) was slowly added under an ice bath condition, and the mixture was continuously stirred for 2 h at room temperature. When TLC indicated that the reaction was complete, water was added to quench the reaction, and it was extracted by ethyl acetate, washed with brine, dried with anhydrous Na2SO4, and concentrated in vacuo. The product was purified via chromatography on a column of silica gel (dichloromethane: methanol = 20:1) to offer a white solid (9.63 g, 66%), mp 100–101 °C. 1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.22−7.14 (m, 3H), 7.06 (t, J = 7.2 Hz, 1H), 7.02 (d, J = 2.4 Hz, 1H), 5.12 (d, J = 9.2 Hz, 1H), 4.29−4.17 (m, 1H), 3.43 (s, 3H), 3.23 (d, J = 5.6 Hz, 2H), 2.37 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.8, 143.5, 136.4, 136.1, 129.5, 127.1, 123.6, 122.1, 119.6, 118.4, 111.4, 108.8, 56.0, 52.5, 29.2, 21.5.

3.2.3. General Procedures for the Preparation of Compounds 3a–3c

A mixture of compound 2 (2 mmol) and K2CO3 (1.5 equiv) in DMF (10 mL) was stirred at 0oC for 30 min; then, 2-bromoacetophenones (1.2 equiv) were added and the mixture was warmed naturally to room temperature and stirred till the complete consumption of the starting materials. When TLC indicated that the reaction was complete, the reaction was quenched with ice-cold water and extracted with ethyl acetate. The combined organic layer was washed with ice-cold water and saturated with aqueous ammonium chloride, dried with anhydrous Na2SO4, concentrated in vacuo, and then purified by chromatography on a column of silica gel to offer 3a–3c.
(S)-3-methyl (1H-indol-3-yl)-2-(4-methyl-N-(2-oxo-2-phenylethyl)phenylsulfon-amido)propanoate (3a):
Yellow solid, yield 80%, mp 118–120 °C. 1H NMR (400 MHz, CDCl3) δ 7.99−7.93 (m, 3H), 7.84 (d, J = 8.4 Hz, 2H), 7.60 (t, J = 7.6 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.41 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.24 (d, J = 8.0 Hz, 2H), 7.17 (t, J = 7.2 Hz, 1H), 7.10−7.05 (m, 1H), 6.95 (d, J = 2.4 Hz, 1H), 5.11 (d, J = 1.6 Hz, 2H), 4.65 (dd, J = 9.7, 5.3 Hz, 1H), 3.42 (s, 3H), 3.24 (dd, J = 14.0, 9.6 Hz, 1H), 3.14 (dd, J = 14.0, 5.2 Hz, 1H), 2.41 (s, 3H). 13C NMR (100 MHz, DMSO) δ 189.1, 166.1, 138.5, 131.3, 130.9, 129.8, 128.4, 124.1, 123.6, 122.9, 122.8, 121.7, 118.1, 116.8, 114.3, 113.1, 106.1, 104.3, 54.0, 46.8, 44.8, 21.6, 16.4.
(S)-methyl 3-(1H-indol-3-yl)-2-(N-(2-(4-methoxyphenyl)-2-oxoethyl)-4-methylphenylsulfonamido)propanoate (3b):
Yellow solid, yield 67%, mp 100–102 °C. 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.83 (d, J = 7.6 Hz, 2H), 7.39 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.14 (t, J = 7.6 Hz, 1H), 7.05 (t, J = 7.6 Hz, 1H), 6.96−6.90 (m, 3H), 5.06 (s, 2H), 4.64 (dd, J = 9.6, 5.2 Hz, 1H), 3.87 (s, 3H), 3.39 (s, 3H), 3.23 (dd, J = 14.0, 9.6 Hz, 1H), 3.13 (dd, J = 14.0, 5.2 Hz, 1H), 2.38 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 192.7, 171.3, 163.9, 143.6, 136.6, 136.1, 130.3, 129.3, 128.1, 128.1, 127.0, 123.4, 122.0, 119.5, 118.4, 114.0, 111.2, 109.8, 59.3, 55.6, 52.0, 49.7, 26.8, 21.6.
(S)-methyl2-(N-(2-(4-chlorophenyl)-2-oxoethyl)-4-methylphenylsulfonamido)-3-(1H-indol-3-yl)propanoate (3c):
White solid, yield 62%, mp 80–81 °C. 1H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.90 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.24 (d, J = 8.0 Hz, 2H), 7.17 (t, J = 7.2 Hz, 1H), 7.08 (t, J = 7.2 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 5.05 (s, 2H), 4.64 (dd, J = 9.6, 5.6 Hz, 1H), 3.42 (s, 3H), 3.23 (dd, J = 14.0, 9.6 Hz, 1H), 3.13 (dd, J = 14.0, 5.2 Hz, 1H), 2.41 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 193.2, 171.3, 143.7, 140.1, 136.4, 136.1, 133.4, 129.4, 129.4, 129.1, 128.1, 127.0, 123.2, 122.1, 119.6, 118.4, 111.2, 109.7, 59.1, 52.1, 49.9, 26.8, 21.6.

3.2.4. General Procedures for the Preparation of Compounds 4a–4c

A solution of 3 (0.5 mmol) in 1,2-dichloroethane was added with trifluoromethanesulfonic acid (0.2 equiv) and stirred at room temperature. When TLC indicated that the reaction was complete, water was added, and it was extracted with dichloromethane; then, the combined organic phases were washed with brine, dried over anhydrous Na2SO4, concentrated in vacuo, and finally, purified by chromatography on a column of silica gel (petroleum ether: ethyl acetate = 5:1) to obtain the desired product 4a–4c.
(S)-methyl 5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carboxylate (4a):
Yellow solid, yield 84%, mp 88–90 °C. 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.4 Hz, 2H), 7.52 (s, 1H), 7.48−7.38 (m, 6H), 7.32 (d, J = 8.0 Hz, 2H), 7.15−7.03 (m, 3H), 6.98 (d, J = 0.4 Hz, 1H), 5.57 (t, J = 3.6 Hz, 1H), 3.92 (dd, J = 16.0, 4.8 Hz, 1H), 3.28 (s, 3H), 2.79 (dd, J = 16.0, 3.2 Hz, 1H), 2.42 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 168.0, 144.4, 138.7, 135.6, 135.1, 131.2, 130.0, 129.7, 129.0, 128.4, 128.0, 127.3, 124.4, 122.4, 119.7, 117.7, 116.5, 110.7, 110.6, 57.6, 52.2, 28.3, 21.7.
(S)-methyl 5-(4-methoxyphenyl)-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carboxylate (4b):
Yellow solid, yield 65%, mp 95–97 °C. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.0 Hz, 2H), 7.56 (s, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.31 (t, J = 8.4 Hz, 4H), 7.14−7.03 (m, 3H), 6.96 (d, J = 8.4 Hz, 2H), 6.93 (s, 1H), 5.56 (s, 1H), 3.90 (dd, J = 16.0, 4.8 Hz, 1H), 3.86 (s, 3H), 3.27 (s, 3H), 2.77 (dd, J = 16.0, 2.4 Hz, 1H), 2.40 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 168.1, 159.5, 144.3, 135.7, 135.1, 131.6, 130.9, 130.9, 129.9, 128.5, 127.3, 124.0, 122.3, 119.7, 117.7, 116.3, 114.3, 110.7, 110.5, 57.7, 55.4, 52.2, 28.2, 21.6.
(S)-methyl 5-(4-chlorophenyl)-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carboxylate (4c):
Yellow solid, yield 68%, mp 94–96 °C. 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.4 Hz, 2H), 7.52 (s, 1H), 7.46 (d, J = 7.2 Hz, 1H), 7.44−7.38 (m, 2H), 7.37−7.29 (m, 4H), 7.16−7.04 (m, 3H), 6.97 (s, 1H), 5.59−5.51 (m, 1H), 3.91 (dd, J = 16.0, 5.2 Hz, 1H), 3.24 (s, 3H), 2.76 (dd, J = 16.0, 2.8 Hz, 1H), 2.41 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.9, 144.6, 137.2, 135.4, 135.2, 134.0, 131.0, 130.9, 130.0, 129.2, 128.4, 127.3, 124.5, 122.5, 119.9, 117.7, 115.0, 110.9, 110.8, 57.7, 52.2, 28.3, 21.7.

3.2.5. General Procedures for the Preparation of Compounds 5a–5c

Ta a solution of 4 (1 equiv) in ethanol (20 mL), 80% NH2NH2·H2O (10 equiv) was slowly added at room temperature; then, the mixture was stirred for about 4~5 h, and the precipitate was gradually generated. When TLC indicated that the reaction was complete, the precipitate was filtered and dried in vacuo.
(S)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (5a):
White solid, yield 83%, mp 135–137 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.04 (s, 1H), 9.12 (s, 1H), 7.73 (d, J = 7.2 Hz, 2H), 7.54−7.34 (m, 8H), 7.24 (d, J = 7.6 Hz, 1H), 7.05−6.82 (m, 3H), 5.27 (s, 1H), 3.98 (s, 2H), 3.79 (d, J = 11.2 Hz, 1H), 2.36 (s, 3H), 2.29 (d, J = 15.6 Hz, 1H). 13C NMR (100 MHz, DMSO-d6) δ 166.1, 144.3, 139.2, 135.8, 134.7, 131.1, 130.1, 129.1, 128.6, 127.9, 127.5, 127.0, 124.2, 121.2, 118.6, 117.4, 111.5, 110.3, 58.9, 26.9, 21.0. HRMS (ESI) calcd. for C26H24N4O3S (M+H)+ 473.1647, found 473.1639.
(S)-5-(4-methoxyphenyl)-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carboh-ydrazide (5b):
Yellow solid, yield 35%, mp 150–152 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.00 (s, 1H), 9.09 (s, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 7.6 Hz, 3H), 7.34 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 7.6 Hz, 1H), 7.04 (d, J = 8.4 Hz, 2H), 6.95 (dt, J = 14.8, 6.8 Hz, 2H), 6.84 (s, 1H), 5.26 (s, 1H), 4.00 (s, 2H), 3.82 (s, 3H), 3.74 (dd, J = 15.6, 5.2 Hz, 1H), 2.35 (s, 3H), 2.28 (d, J = 14.8 Hz, 1H). 13C NMR (100 MHz, DMSO-d6) δ 166.2, 158.8, 144.2, 135.8, 134.8, 131.5, 131.3, 130.3, 130., 127.8, 126.9, 123.4, 121.2, 118.6, 117.6, 117.4, 114.0, 111.5, 110.1, 59.2, 55.2, 26.8, 21.0. HRMS (ESI) calcd. for C27H26N4O4S (M+H)+ 503.1753, found 503.1746.
(S)-5-(4-chlorophenyl)-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohyd-razide (5c):
Yellow solid, yield 32%, mp 144–145 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.07 (s, 1H), 9.09 (s, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 8.4 Hz, 4H), 7.37 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.01−6.90 (m, 2H), 6.89 (s, 1H), 5.24 (d, J = 2.8 Hz, 1H), 3.95 (s, 2H), 3.78 (dd, J = 16.0, 5.2 Hz, 1H), 2.37 (s, 3H), 2.21 (dd, J = 16.0, 2.8 Hz, 1H). 13C NMR (100 MHz, DMSO-d6) δ 165.9, 144.4, 138.0, 135.8, 134.5, 132.2, 131.1, 130.8, 130.2, 128.6, 127.9, 127.1, 124.3, 121.3, 118.7, 117.4, 115.5, 111.4, 110.3, 58.4, 26.9, 21.0. HRMS (ESI) calcd. for C26H23ClN4O3S (M+H)+ 507.1257, found 507.1251.

3.2.6. General Procedures for the Preparation of Compounds 6a–6c

A mixture of 5 (1.0 equiv.) and p-chlorobenzaldehyde (1.5 equiv) in ethanol (30 mL) was heated to 100 °C. When TLC indicated that the reaction was complete, the mixture was concentrated in vacuo, and then purified by chromatography on a column of silica gel (petroleum ether: ethyl acetate = 2:1) to offer 6a–6c.
(S)-N’-(4-chlorobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6a):
Yellow solid 0.42 g, yield 83%, mp 147–149 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.42 and 11.19 (s, 1H), 10.27 and 10.15 (s, 1H), 8.19 and 7.89 (s, 1H), 7.88−6.76 (m, 18H), 6.07−6.01 and 5.45−5.40 (m, 1H), 4.12 and 3.87 (dd, J = 15.6, 5.6 Hz, 1H), 2.75−2.67 and 2.46−2.42 (m, 1H), 2.40 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 168.0, 163.9, 146.4, 145.0, 144.8, 142.8, 140.0, 139.6, 136.5, 136.4, 135.7, 135.2, 135.0, 134.9, 133.5, 133.4, 132.8, 131.9, 130.7, 129.7, 129.5, 129.3, 129.1, 129.0, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 125.2, 124.6, 121.8, 121.5, 119.2, 119.1, 117.5, 116.7, 115.3, 112.1, 110.4, 109.9, 59.9, 27.6, 27.3, 21.6. HRMS (ESI) calcd. for C33H27ClN4O3S (M+H)+ 595.1570, found 595.1564.
(S)-N’-(4-chlorobenzylidene)-5-(4-methoxyphenyl)-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6b):
Yellow solid 0.30 g, yield 60%, mp 240–242 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.44 and 11.21 (s, 1H), 10.26 and 10.14 (s, 1H), 8.22 and 7.91 (s, 1H), 7.89−6.77 (m, 17H), 6.07 and 5.44 (s, 1H), 4.12 (dd, J = 15.2, 5.6 Hz, 1H), 3.83 (s, 3H), 2.72 and 2.45 (d, J = 14.8 Hz, 1H), 2.40 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 168.1, 164.0, 163.2, 159.4, 159.2, 144.7, 142.7, 136.42, 136.37, 135.8, 135.0, 134.9, 133.5, 133.4, 133.2, 132.3, 132.2, 131.7, 130.7, 130.6, 130.5, 129.7, 129.3, 129.1, 129.0, 128.1, 127.8, 127.5, 127.4, 124.3, 123.8, 121.7, 121.4, 119.2, 119.1, 117.9, 117.58, 117.56, 116.7, 115.5, 114.7, 112.1, 110.2, 109.7, 60.1, 59.7, 56.5, 55.7, 27.5, 27.3, 21.6, 19.1. HRMS (ESI) calcd. for C34H29ClN4O4S (M+H)+ 625.1676, found 625.1674.
(S)-N’-(4-chlorobenzylidene)-5-(4-chlorophenyl)-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6c):
Yellow solid 0.39 g, yield 79%, mp 153–155 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.42 and 11.19 (s, 1H), 10.33 and 10.21 (s, 1H), 8.25−6.76 (m, 18H), 6.05 (d, J = 2.8 Hz, 0.6H) and 5.44 (s, 0.4H), 4.15 and 3.91 (dd, J = 15.6, 5.6 Hz, 1H), 2.70 (d, J = 14.0 Hz, 1H), 2.41 and 2.38 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.8, 163.7, 146.5, 145.1, 144.9, 142.8, 138.9, 138.5, 136.5, 136.4, 135.6, 135.04, 134.98, 133.5, 133.4, 132.8, 132.5, 131.7, 131.5, 131.1, 130.7, 129.7, 129.3, 129.2, 129.1, 129.0, 128.2, 127.8, 127.6, 127.5, 125.3, 124.7, 121.9, 121.6, 119.3, 119.2, 117.6, 116.7, 115.8, 113.8, 112.0, 110.4, 109.9, 59.5, 59.4, 27.7, 27.4, 21.6. HRMS (ESI) calcd. for C33H26ClN4O3S (M+H)+ 629.1181, found 629.1171.

3.2.7. General Procedures for the Preparation of Compounds 6d–6aa

To a solution of 5a (0.4 g, 0.85 mmol) in ethanol (30 mL), the corresponding aldehyde (1.5 equiv) was added, and then the mixture was heated to 100 °C. When TLC indicated that the reaction was complete, the mixture was concentrated in vacuo, and then purified by chromatography on a column of silica gel (petroleum ether: ethyl acetate = 2:1) to offer 6d–6aa.
(S)-N’-benzylidene-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6d):
Yellow solid 0.41 g, yield 88%, mp 222–224 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.35 and 11.12 (s, 1H, Ar-NH), 10.28 and 10.15 (s, 1H), 8.21−6.72 (m, 20H), 6.04 and 5.42 (m, 1H), 4.14 and 3.88 (dd, J = 15.6, 5.6 Hz, 1H), 2.70 and 2.39 (dd, J = 15.6, 5.6 Hz, 1H), 2.40 and 2.38 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.9, 163.7, 147.7, 145.0, 144.8, 144.0, 140.0, 139.6, 136.5, 136.4, 135.7, 135.2, 134.6, 134.4, 133.4, 132.8, 131.9, 130.7, 130.6, 130.5, 129.7, 129.6, 129.5, 129.3, 129.2, 129.1, 128.2, 128.1, 127.9, 127.8, 127.6, 127.49, 127.45, 127.4, 125.2, 124.6, 121.7, 121.5, 119.2, 119.1, 117.5, 117.4, 116.6, 115.2, 112.1, 110.3, 109.9, 59.9, 59.8, 27.6, 27.2, 22.7, 21.6. HRMS (ESI) calcd. for C33H28N4O3S (M+H)+ 561.1960, found 561.1954.
(S)-N’-(4-nitrobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6e):
Yellow solid 0.43 g, yield 84%, mp 155–157 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.69 and 11.44 (s, 1H), 10.29 and 10.16 (s, 1H), 8.42−6.74 (m, 19H), 6.08 and 5.45 (dd, J = 4.8, 2.4 Hz, 1H), 4.13 and 3.89 (dd, J = 16.0, 5.6 Hz, 1H), 2.72 (dd, J = 16.0, 2.4 Hz, 1H), 2.40 and 2.38 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.7, 163.7, 147.9, 147.8, 144.7, 144.5, 144.4, 141.3, 140.2, 139.5, 139.1, 136.0, 135.9, 135.1, 134.6, 132.2, 131.4, 130.2, 129.0, 128.8, 127.9, 127.8, 127.6, 127.4, 127.2, 127.0, 126.9, 124.6, 124.3, 124.0, 123.9, 121.3, 121.0, 118.71, 118.67, 117.04, 117.01, 116.2, 114.8, 111.6, 109.8, 109.3, 59.4, 59.3, 27.1, 26.9, 21.1. HRMS (ESI) calcd. for C33H27N5O5S (M+H)+ 606.1811, found 606.1809.
(S)-N’-(4-methoxybenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6f):
Yellow solid 0.46 g, yield 92%, mp 232–234 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.20 and 10.99 (s, 1H), 10.28 and 10.15 (s, 1H), 8.11 and 7.82 (s, 1H), 7.77 (t, J = 8.8 Hz, 3H), 7.52−6.75 (m, 15H), 6.01 and 5.39 (s, 1H), 4.14 (dd, J = 15.6, 5.6 Hz, 1H), 3.86 and 3.76 (s, 3H), 2.67 (d, J = 14.8 Hz, 1H), 2.40 and 2.38 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.2, 163.04, 163.01, 160.9, 160.8, 147.2, 144.5, 144.4, 143.4, 139.6, 139.2, 136.0, 135.3, 134.7, 132.3, 131.5, 130.3, 129.6, 129.1, 128.8, 128.6, 128.5, 127.7, 127.6, 127.6, 127.4, 127.4, 127.1, 127.0, 126.7, 126.5, 126.5, 124.8, 124.2, 121.3, 121.0, 118.74, 118.66, 117.11, 117.08, 116.9, 116.2, 114.7, 114.6, 114.2, 111.7, 110.0, 109.5, 59.5, 59.3, 55.4, 55.3, 27.2, 26.8, 21.1. HRMS (ESI) calcd. for C34H30N4O4S (M+H)+ 591.2066, found 591.2066.
(S)-N’-(3-methoxybenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6g):
Yellow solid 0.40 g, yield 80%, mp 230–232 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.38 and 11.19 (s, 1H), 10.30 and 10.17 (s, 1H), 8.18 and 7.89 (s, 1H), 7.84−6.75 (m, 18H), 6.04 and 5.45 (s, 1H), 4.10 and 3.92 (dd, J = 15.2, 5.2 Hz, 1H), 3.86 and 3.73 (s, 3H), 2.70 and 2.45 (d, J = 15.2 Hz, 1H), 2.38 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 168.0, 163.7, 160.2, 159.9, 147.6, 145.0, 144.8, 143.7, 140.0, 139.7, 136.5, 136.4, 136.0, 135.9, 135.6, 135.2, 132.8, 132.0, 130.7, 130.7, 130.3, 129.6, 129.2, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 125.2, 124.6, 121.8, 121.5, 120.6, 119.9, 119.1, 117.5, 117.3, 116.9, 116.7, 116.4, 115.7, 112.2, 112.1, 111.2, 110.3, 110.0, 60.1, 59.7, 55.6, 55.5, 27.7, 27.1, 21.6. HRMS (ESI) calcd. for C34H30N4O4S (M+H)+ 591.2066, found 591.2063.
(S)-N’-(2-methoxybenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6h):
Yellow solid 0.42 g, yield 84%, mp 134–136 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.38 and 11.10 (s, 1H), 10.29 and 10.16 (s, 1H), 8.57 and 8.24 (s, 1H), 8.06−6.75 (m, 18H), 6.05 and 5.40 (d, J = 3.0 Hz, 1H), 4.16 (dd, J = 15.6, 5.6 Hz, 0.6 H) and 3.91 (dd, J = 9.6, 5.6Hz, 0.4H), 3.86 and 3.85 (s, 3H), 2.71 and 2.42 (dd, J = 15.2, 2.0Hz, 1H), 2.39 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.8, 163.6, 158.2, 158.1, 144.8, 143.2, 140.0, 139.8, 139.6, 136.5, 136.4, 135.7, 135.2, 132.8, 132.0, 131.9, 130.8, 130.7, 129.6, 129.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 125.9, 125.8, 125.2, 124.7, 122.6, 122.4, 121.8, 121.54, 121.49, 121.1, 119.2, 119.1, 117.6, 117.5, 116.7, 115.3, 112.5, 112.2, 112.1, 110.5, 109.9, 59.9, 59.8, 56.2, 56.1, 27.5, 27.2, 21.6. HRMS (ESI) calcd. for C34H30N4O4S (M+H)+ 591.2066, found 591.2063.
(S)-N’-(3-nitrobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6i):
Deep-yellow solid 0.43 g, yield 84%, mp 249–252 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.66 and 11.43 (s, 1H), 10.31 and 10.18 (s, 1H), 8.68−6.73 (m, 19H), 6.11 and 5.49 (s, 1H), 4.08 and 3.92 (d, J = 12.0 Hz, 1H), 2.70 and 2.45 (d, J = 15.2 Hz, 1H), 2.40 and 2.38 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 168.3, 164.2, 148.9, 148.6, 145.3, 145.0, 144.9, 141.8, 139.9, 139.6, 136.5, 136.4, 136.3, 136.2, 135.5, 135.2, 133.7, 133.4, 132.8, 132.0, 131.1, 130.8, 130.7, 129.5, 129.3, 128.1, 127.9, 127.8, 127.5, 127.4, 125.1, 124.8, 124.7, 124.6, 121.8, 121.7, 121.5, 121.4, 119.2, 117.5, 116.7, 115.7, 112.1, 110.3, 109.9, 59.9, 27.7, 27.2, 21.6. HRMS (ESI) calcd. for C33H27N5O5S (M+H)+ 606.1811, found 606.1806.
(S)-N’-(4-cyanobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6j):
Yellow solid 0.41 g, yield 83%, mp 157–159 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.64 and 11.40 (s, 1H), 10.31 and 10.18 (s, 1H), 8.31−6.75 (m, 19H), 6.10 and 5.48 (s, 1H), 4.14 and 3.92 (dd, J = 15.2, 5.2 Hz, 1H), 2.75 and 2.47 (d, J = 15.2 Hz, 1H), 2.40 and 2.38 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 168.2, 164.1, 145.8, 145.0, 144.9, 142.2, 140.0, 139.6, 139.0, 138.9, 136.5, 135.7, 135.1, 133.5, 133.1, 132.8, 131.9, 130.7, 129.5, 129.3, 128.1, 128.0, 127.9, 127.7, 127.5, 125.1, 124.5, 121.8, 121.5, 119.22, 119.17, 117.5, 116.7, 115.3, 112.42, 112.36, 112.1, 110.3, 109.8, 59.9, 27.6, 27.4, 21.6. HRMS (ESI) calcd. for C34H27N5O3S (M+H)+ 586.1913, found 586.1914.
(S)-N’-(4-tert-butylbenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6k):
Yellow solid 0.43 g, yield 83%, mp 150–152 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.28 and 11.07 (s, 1H), 10.28 and 10.15 (s, 1H), 8.15 and 7.86 (s, 1H), 7.81−6.77 (m, 18H), 6.02 and 5.40 (d, J = 2.8 Hz, 1H), 4.12 and 3.87 (dd, J = 15.6, 5.6 Hz, 1H), 2.67 (d, J = 13.6 Hz, 1H), 2.40 and 2.38 (s, 3H), 1.35 and 1.25 (s, 9H). 13C NMR (100 MHz, DMSO-d6) δ 167.9, 163.6, 153.3, 147.7, 144.9, 144.8, 143.9, 140.0, 139.6, 136.5, 135.7, 135.2, 132.8, 131.9, 131.9, 131.7, 130.7, 129.5, 129.3, 128.2, 128.1, 127.8, 127.6, 127.5, 127.3, 127.2, 126.4, 126.0, 125.2, 124.6, 121.8, 121.5, 119.2, 119.1, 117.5, 116.6, 115.3, 112.1, 110.4, 109.9, 59.9, 35.1, 35.0, 31.5, 27.7, 27.2, 21.6. HRMS (ESI) calcd. for C37H36N4O3S (M+H)+ 617.2586, found 617.2578.
(S)-N’-(4-(dimethylamino)benzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6l):
Yellow solid 0.35 g, yield 68%, mp 146–148 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.01 and 10.83 (s, 1H), 10.27 and 10.15 (s, 1H), 8.06−6.61 (m, 19H), 6.02 and 5.40 (s, 1H), 4.19 and 3.88 (d, J = 11.2 Hz, 1H), 3.01 and 2.91 (s, 6H), 2.68 (d, J = 15.2 Hz, 1H), 2.39 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.4, 163.2, 152.0, 144.9, 144.8, 144.7, 140.1, 139.7, 136.5, 136.4, 135.8, 135.2, 132.8, 132.0, 130.7, 129.5, 129.3, 128.8, 128.6, 128.2, 128.1, 127.9, 127.6, 127.5, 125.3, 124.7, 122.0, 121.73, 121.69, 121.5, 119.2, 119.1, 117.6, 117.5, 116.7, 115.3, 112.5, 112.1, 110.5, 110.1, 60.0, 59.8, 40.3, 27.8, 27.1, 21.6. HRMS (ESI) calcd. for C35H33N5O3S (M+H)+ 604.2382, found 604.2382.
(S)-N’-(biphenyl-4-ylmethylene)-5-phenyl-3-tosyl-1,2,3,-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6m):
Yellow solid 0.42 g, yield 78%, mp 153–155 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.42 and 11.20 (s, 1H), 10.31 and 10.19 (s, 1H), 8.25 and 7.96 (s, 1H), 7.94−6.78 (m, 23H), 6.15−6.04, 5.50−5.37 (m, 1H), 4.19 and 3.92 (dd, J = 15.6, 5.6 Hz, 1H), 2.74, 2.46 (d, J =14.0 Hz, 1H), 2.40 and 2.38 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.4, 163.3, 146.8, 144.5, 144.4, 143.1, 141.6, 141.5, 139.5, 139.4, 139.2, 139.1, 136.0, 135.9, 135.2, 134.7, 133.2, 133.0, 132.3, 131.5, 130.2, 129.1, 129.0, 128.8, 128.7, 127.92, 127.85, 127.7, 127.6, 127.5, 127.3, 127.3, 127.1, 127.0, 126.9, 126.7, 126.6, 124.7, 121.0, 118.71, 118.66, 117.1, 117.0, 116.2, 114.7, 111.6, 109.9, 109.4, 59.4, 27.1, 26.8, 21.1. HRMS (ESI) calcd. for C39H32N4O3S (M+H)+ 637.2273, found 637.2267.
(S)-N’-(3-chlorobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6n):
Yellow solid 0.39 g, yield 79%, mp 247–249 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.53 and 11.30 (s, 1H), 10.31 and 10.18 (s, 1H), 8.20 and 7.91 (s, 1H), 7.89−6.78 (m, 18H), 6.08 and 5.46 (s, 1H), 4.07 and 3.91 (dd, J = 15.2, 5.2 Hz, 1H), 2.74 (d, J = 15.2 Hz, 0.6H) and 2.45 (d, J = 17.6 Hz, 0.4H), 2.39 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.7, 163.5, 145.5, 144.5, 144.3, 142.0, 139.4, 139.1, 136.3, 136.2, 136.0, 135.9, 135.1, 134.7, 133.9, 133.6, 132.3, 131.5, 131.0, 130.6, 130.2, 130.2, 129.7, 129.6, 129.0, 128.8, 128.7, 127.7, 127.6, 127.4, 127.3, 127.0, 126.3, 126.2, 125.7, 125.5, 124.7, 124.1, 121.3, 121.0, 118.71, 118.67, 117.04, 116.98, 116.2, 115.2, 111.6, 109.8, 109.5, 59.6, 59.3, 27.1, 26.7, 21.1. HRMS (ESI) calcd. for C33H27ClN4O3S (M+H)+ 595.1570, found 595.1563.
(S)-N’-(2-chlorobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6o):
Yellow solid 0.46 g, yield 92%, mp 132–134 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.63 and 11.33 (s, 1H), 10.31 and 10.17 (s, 1H), 8.62 and 8.31 (s, 1H), 8.25−6.76 (m, 18H), 6.08 and 5.46 (s, 1H), 4.14 (d, J = 11.8 Hz, 0.6H) and 3.93 (d, J = 13.2 Hz, 0.4H), 2.74 and 2.44 (d, J = 15.2 Hz, 1H), 2.39 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 168.0, 163.9, 145.0, 144.8, 143.8, 140.3, 140.0, 139.6, 136.5, 136.5, 135.7, 135.1, 133.6, 132.8, 132.0, 131.9, 131.8, 131.7, 130.7, 130.6, 130.3, 129.5, 129.3, 128.5, 128.2, 128.1, 127.94, 127.87, 127.8, 127.6, 127.5, 127.4, 127.2, 125.2, 124.5, 121.8, 121.6, 119.2, 117.6, 116.7, 115.4, 112.1, 110.5, 109.9, 59.9, 27.5, 27.4, 21.6. HRMS (ESI) calcd. for C33H27ClN4O3S (M+H)+ 595.1570, found 595.1568.
(S)-N’-(2,4-dichlorobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6p):
Yellow solid 0.39 g, yield 74%, mp 140–142 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.65 and 11.36 (s, 1H), 10.29 and 10.16 (s, 1H), 8.57 and 8.24 (s, 1H), 8.22−6.77 (m, 17H), 6.07 and 5.45 (s, 1H), 4.16−4.05 and 3.96−3.85 (m, 1H), 2.73 and 2.42 (d, J = 15.2 Hz, 1H), 2.39 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 168.0, 164.0, 145.0, 144.9, 142.8, 140.0, 139.6, 139.4, 136.5, 136.4, 135.7, 135.6, 135.6, 135.1, 134.2, 132.8, 131.8, 130.9, 130.8, 130.7, 130.1, 129.8, 129.5, 129.3, 128.8, 128.6, 128.4, 128.3, 128.2, 128.1, 127.9, 127.7, 127.60, 127.5, 125.1, 124.5, 121.8, 121.6, 119.2, 117.70, 117.65, 116.7, 115.4, 112.1, 110.5, 109.8, 60.0, 59.8, 27.4, 21.6. HRMS (ESI) calcd. for C33H26Cl2N4O3S (M+H)+ 629.1181, found 629.1175.
(S)-N’-(3,4-dichlorobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6q):
Yellow solid 0.48 g, yield 75%, mp 144–146 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.59 and 11.33 (s, 1H), 10.30 and 10.17 (s, 1H), 8.18 and 8.04 (s, 1H), 7.91−6.77 (m, 17H), 6.06 and 5.45 (d, J = 2.8 Hz, 1H), 4.06 and 3.89 (dd, J = 15.6, 5.6 Hz, 1H), 2.72 and 2.44 (d, J = 14.0 Hz, 1H), 2.39 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.7, 163.5, 144.5, 144.4, 141.0, 139.4, 139.1, 136.0, 135.9, 135.1, 134.9, 134.8, 134.7, 132.3, 132.2, 131.9, 131.6, 131.3, 130.9, 130.2, 130.2, 129.0, 128.8, 128.7, 128.6, 128.4, 127.6, 127.5, 127.4, 127.2, 127.0, 126.8, 126.5, 124.6, 124.1, 121.3, 121.0, 118.7, 117.0, 116.9, 116.2, 115.2, 111.6, 109.8, 109.4, 59.5, 59.3, 27.1, 26.8, 21.1. HRMS (ESI) calcd. for C33H26Cl2N4O3S (M+H)+ 629.1181, found 629.1178.
(S)-N’-(3,4-dimethoxybenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6r):
Yellow solid 0.46 g, yield 87%, mp 146–148 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.19 and 11.04 (s, 1H), 10.27 and 10.13 (s, 1H), 8.09 and 7.81 (s, 1H), 7.80−6.76 (m, 17H), 6.01−5.95 and 5.41−5.37 (m, 1H), 4.06 (dd, J = 15.2, 5. 6Hz, 1H), 3.87 and 3.76 (s, 3H), 3.85 and 3.71 (s, 3H), 2.61 and 2.41 (dd, J = 15.6, 2.4 Hz, 1H), 2.39 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.9, 163.4, 151.2, 151.1, 149.6, 149.4, 147.9, 145.0, 144.8, 143.8, 139.9, 139.7, 136.5, 136.4, 135.6, 135.2, 132.7, 132.0, 130.7, 130.6, 129.6, 129.3, 129.2, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 127.4, 127.1, 125.2, 124.6, 122.5, 121.7, 121.5, 121.3, 119.2, 119.1, 117.5, 117.2, 116.7, 116.1, 112.3, 112.14, 112.10, 111.7, 110.3, 110.2, 109.2, 108.2, 60.2, 59.5, 56.1, 56.0, 55.8, 55.7, 27.7, 27.0, 21.5. HRMS (ESI) calcd. for C35H32N4O5S (M+H)+ 621.2171, found 621.2165.
(S)-N’-(benzo[d][1,3]dioxol-5-ylmethylene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6s):
Yellow solid 0.44 g, yield 87%, mp 143–145 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.23 and 11.00 (s, 1H), 10.26 and 10.14 (s, 1H), 8.10−6.76 (m, 18H), 6.16 and 6.03 (d, J = 2.8 Hz, 1H), 6.03−5.99 and 5.41−5.37 (m, 1H), 4.10 and 3.86 (dd, J = 15.6, 5.6 Hz, 1H), 2.68 and 2.41 (dd, J = 15.6, 2.4 Hz, 1H), 2.39 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.8, 163.6, 149.6, 149.5, 148.7, 148.4, 147.6, 144.9, 144.8, 143.7, 140.0, 139.6, 136.5, 136.4, 135.7, 135.2, 132.7, 131.9, 130.7, 130.6, 129.5, 129.3, 129.2, 129.0, 128.8, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 125.2, 124.6, 123.8, 123.6, 121.8, 121.5, 119.2, 119.1, 117.6, 117.5, 116.7, 115.3, 112.1, 110.4, 110.0, 109.1, 108.8, 105.5, 105.5, 102.1, 102.0, 60.0, 59.8, 27.7, 27.2, 21.6. HRMS (ESI) calcd. for C34H28N4O5S (M+H)+ 605.1858, found 605.1852.
(S)-N’-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6t):
Yellow solid 0.35 g, yield 85%, mp 148–150 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.23 and 11.02 (s, 1H), 10.28 and 10.16 (s, 1H), 8.07−6.77 (m, 18H), 6.01 and 5.40 (s, 1H), 4.34 (s, 3H), 4.18 (s, 1H), 4.09 and 3.87 (dd, J = 15.6, 5.6 Hz, 1H), 2.69 and 2.41 (d, J = 14.0 Hz, 1H), 2.40 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 172.5, 168.3, 152.2, 150.5, 150.4, 149.7, 149.6, 149.0, 148.7, 148.3, 144.8, 144.4, 141.2, 141.1, 140.4, 139.9, 137.5, 136.7, 135.5, 134.3, 134.0, 132.9, 132.82, 132.78, 132.6, 132.5, 132.3, 132.2, 130.0, 129.3, 126.5, 126.2, 125.9, 125.8, 123.9, 123.8, 123.0, 122.6, 122.3, 122.2, 121.4, 120.4, 120.2, 120.0, 116.8, 115.1, 114.7, 69.6, 69.5, 69.3, 69.2, 64.7, 64.6, 32.4, 31.9, 26.3. HRMS (ESI) calcd. for C35H30N4O5S (M+H)+ 619.2015, found 619.2018.
(S)-N’-(3,5-di-tert-butyl-4-hydroxybenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6u):
Yellow solid 0.50 g, yield 86%, mp 160–162 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.09 and 11.04 (s, 1H), 10.32 and 10.16 (s, 1H), 8.10 and 7.82 (s, 1H), 7.78 and 7.74 (d, J = 8.4 Hz, 2H), 7.59−6.79 (m, 15H), 5.94 (s, 1H), 5.42 (s, 1H), 4.08−3.99 and 3.93−3.85 (m, 1H), 2.53 and 2.42 (s, 1H), 2.40 and 2.38 (s, 3H), 1.47 and 1.36 (s, 18H). 13C NMR (100 MHz, DMSO-d6) δ 167.9, 163.3, 156.6, 156.5, 149.3, 144.9, 144.8, 144.5, 139.9, 139.8, 139.7, 139.6, 136.5, 136.4, 135.2, 135.1, 132.8, 131.9, 130.7, 130.7, 129.6, 129.3, 128.2, 128.0, 127.9, 127.7, 127.6, 127.4, 126.1, 125.7, 125.2, 124.6, 124.3, 124.0, 121.7, 121.5, 119.2, 117.5, 117.1, 116.6, 116.0, 112.2, 112.1, 110.3, 110.0, 60.2, 59.4, 35.1, 34.9, 30.6, 26.5, 21.6, 21.5. HRMS (ESI) calcd. for C41H44N4O4S (M+H)+ 689.3161, found 689.3163.
(S)-N’-(4-bromo-2,6-difluorobenzylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6v):
Yellow solid 0.27 g, yield 47%, mp 199–201 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.55 and 11.34 (s, 1H), 10.30 and 10.16 (s, 1H), 8.33 and 7.96 (s, 1H), 7.80−6.80 (m, 16H), 6.01−5.86 and 5.47−5.40 (m, 1H), 4.11 (dd, J = 15.6., 5.6 Hz, 1H), 2.57 (dd, J = 15.2, 1.6 Hz, 1H), 2.40 and 2.38 (s, 3H). 13C NMR (101 MHz, DMSO) δ 167.6, 163.3, 160.2 (d, J = 256 Hz), 160.1 (d, J = 256 Hz), 144.5, 144.4, 137.32, 136.0, 134.9, 134.6, 132.8, 132.3, 130.2, 129.0, 128.8, 127.63, 127.60, 127.4, 127.3, 127.1, 126.9, 124.6, 124.0, 122.7 (t, J = 13.0 Hz), 121.3, 121.0, 118.8, 116.5, 116.3, 116.1, 114.6, 111.6, 111.0 (t, J = 13.6 Hz), 109.9, 109.2, 59.41, 59.2, 26.9, 26.2, 21.1. HRMS (ESI) calcd. for C33H25BrF2N4O3S (M+H)+ 675.0877, found 675.0871.
(S)-5-phenyl-N’-(pyridin-3-ylmethylene)-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6w):
Yellow solid 0.35 g, yield 73%, mp 152–154 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.56 and 11.31 (s, 1H), 10.29 and 10.17 (s, 1H), 9.05−6.73 (m, 19H), 6.09, 5.46 (s, 1H), 4.15 and 3.91 (dd, J = 15.6, 4.0 Hz, 1H), 2.73 (d, J = 15.2 Hz, 0.6H) and 2.45 (d, J = 16.4 Hz, 0.4H), 2.39 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 168.1, 164.0, 151.2, 149.1, 149.0, 145.1, 145.0, 144.8, 141.3, 140.0, 139.6, 136.5, 136.4, 135.7, 135.2, 134.0, 133.8, 132.7, 132.0, 130.7, 130.5, 130.4, 129.5, 129.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 125.2, 124.7, 124.6, 124.3, 121.8, 121.5, 119.2, 119.1, 117.6, 117.5, 116.7, 115.5, 112.1, 110.3, 110.0, 60.0, 59.9, 27.6, 27.3, 21.6. HRMS (ESI) calcd. for C32H27N5O3S (M+H)+ 562.1913, found 562.1911.
(S)-5-phenyl-N’-(thiophen-2-ylmethylene)-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6x):
Brown solid, yield 79%, mp 222–224 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.32 and 11.15 (s, 1H), 10.32 and 10.17 (s, 1H), 8.42 and 8.08 (s, 1H), 7.83−6.74 (m, 17H), 6.00−5.79 and 5.46−5.35 (m, 1H), 4.11 (dd, J = 15.4, 5.5 Hz, 0.6H) and 3.89 (dd, J = 15.7, 5.4 Hz, 0.4H), 2.64 (d, J = 14.8 Hz, 1H), 2.40 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.6, 163.6, 145.0, 144.9, 143.0, 140.0, 139.6, 139.5, 139.2, 138.8, 136.5, 136.4, 135.5, 135.1, 132.8, 131.9, 131.4, 131.1, 130.7, 129.6, 129.5, 129.3, 129.1, 128.7, 128.2, 128.1, 128.0, 127.9, 127.7, 127.6, 127.4, 125.2, 124.6, 121.8, 121.5, 119.2, 117.6, 116.6, 115.3, 112.1, 110.3, 109.9, 59.9, 59.7, 27.6, 27.1, 21.6. HRMS (ESI) calcd. for C31H26N4O3S2 (M+H)+ 567.1524, found 567.1526.
(S)-N’-((1H-pyrrol-2-yl)methylene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6y):
Yellow solid 0.33 g, yield 72%, mp 154–156 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.64 and 11.31 (s, 1H), 10.98 and 10.72 (s, 1H), 10.24 and 10.14 (s, 1H), 8.02 and 7.71(s, 1H), 7.81 and 7.77 (d, J = 8.0 Hz, 2H), 7.58−6.74 (m, 13H), 6.51 and 6.38 (s, 1H), 6.22 and 5.38 (s, 1H), 6.07 (s, 1H), 4.34 and 3.87 (dd, J = 15.6, 5.6 Hz, 1H), 2.66 (d, J = 15.2 Hz, 1H), 2.39 and 2.37 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.4, 163.0, 144.9, 144.7, 141.1, 140.2, 139.7, 136.7, 136.5, 136.4, 136.1, 135.2, 132.8, 131.9, 130.7, 130.6, 129.5, 129.2, 128.3, 128.1, 128.0, 127.8, 127.6, 127.5, 127.2, 125.5, 124.7, 122.9, 122.7, 121.7, 121.4, 119.2, 119.0, 117.6, 117.4, 116.8, 114.6, 113.7, 113.4, 112.0, 110.6, 110.2, 109.8, 109.6, 59.9, 27.7, 27.5, 21.6. HRMS (ESI) calcd. for C31H27N5O3S (M+H)+ 550.1913, found 550.1908.
(S)-N’-(2,2-dimethylpropylidene)-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6z):
Yellow solid 0.41 g, yield 89%, mp 137–139 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.92 and 10.65 (s, 1H), 10.26 and 10.14 (s, 1H), 7.76−6.83 (m, 15H), 5.84 and 5.33 (s, 1H), 4.04 and 3.86 (dd, J = 15.6, 4.4 Hz, 1H), 2.54 and 2.41 (s, 1H), 2.38 (s, 3H), 1.20 and 0.92 (s, 9H). 13C NMR (100 MHz, DMSO-d6) δ 167.6, 163.3, 159.1, 154.8, 144.8, 140.0, 139.6, 136.4, 135.5, 135.3, 132.8, 131.9, 130.6, 129.4, 129.2, 128.1, 128.0, 127.8, 127.5, 127.4, 125.2, 124.6, 121.6, 121.4, 119.1, 119.0, 117.6, 117.6, 116.6, 115.2, 112.1, 110.5, 109.9, 59.8, 34.9, 27.6, 27.4, 26.7, 21.5. HRMS (ESI) calcd. for C31H32N4O3S (M+H)+ 541.2273, found 541.2274.
(S)-N’-octylidene-5-phenyl-3-tosyl-1,2,3,6-tetrahydroazepino [4,5-b]indole-2-carbohydrazide (6aa):
Yellow solid, yield 54%, mp 87–88 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.85 and 10.66 (s, 1H), 10.26 and 10.14 (s, 1H), 7.78−6.84 (m, 15H), 5.84 and 5.31 (d, J = 2.8 Hz, 1H), 4.00 and 3.81 (dd, J = 15.6, 5.6 Hz, 1H), 2.57 and 2.33 (dd, J = 15.2, 2.0 Hz, 1H), 2.37 (s, 3H), 2.02 and 1.58 (tq, J = 14.8, 7.2 Hz, 2H), 1.47−1.11 (m, 10H), 0.94−0.77 (m, 3H). 13C NMR (100 MHz, DMSO-d6) δ 166.9, 162.6, 151.7, 147.9, 144.4, 144.3, 139.6, 139.2, 136.0, 135.9, 135.1, 134.7, 132.3, 131.4, 130.2, 130.1, 129.0, 128.7, 127.6, 127.5, 127.4, 127.3, 127.0, 126.9, 124.8, 124.1, 121.2, 120.9, 118.6, 118.5, 117.0, 116.9, 116.2, 114.6, 111.6, 109.9, 109.3, 59.1, 54.7, 31.7, 31.6, 31.3, 31.1, 28.7, 28.6, 28.5, 28.4, 26.3, 25.8, 22.2, 22.1, 22.0, 21.0, 14.0, 13.9. HRMS (ESI) calcd. for C34H38N4O3S (M+H)+ 583.2736, found 583.2743.

3.3. Biological Assay

The anti-TMV, larvicidal, and fungicidal activities of the synthesized compounds were tested using our previously reported methods [28,29,30], the detail bioassay procedures are depicted in the Supplemetary Materials, Section S2: Detailed bioassay procedures for anti-TMV activities; Section S3: Stomach toxicity against Plutella xylostella; Section S4: Detailed bioassay procedures for fungicidal activities.

4. Conclusions

In summary, we designed and synthesized a series of novel derivatives containing azepino [4,5-b] indole and acylhydrazone moieties, and first evaluated their biological activities. Most of the compounds showed good to excellent anti-TMV activity compared to commercial ribavirin, among which, compounds 5c, 6a, 6h, 6t, 6v, and 6y displayed excellent anti-TMV activity in vivo. Meanwhile, we were pleased to find that almost all these derivatives showed good larvicidal activity against Plutella xylostella and these derivatives also showed a broad spectrum of fungicidal activity. This systematic study provides strong evidence that the rationality of our speculation and design ideology were preliminarily successful. Further studies on structural optimization are in progress in our laboratory.

Supplementary Materials

The following supporting information can be downloaded at https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/molecules27196700/s1, Section S1: Copies of NMR spectra (Figures S1–S76); Section S2: Detailed bioassay procedures for anti-TMV activities; Section S3: Stomach toxicity against Plutella xylostella; Section S4: Detailed bioassay procedures for fungicidal activities.

Author Contributions

Conceptualization, H.S. and J.Z.; methodology, J.Z. and R.Y.; formal analysis, L.L. and J.L.; data curation, Y.L.; writing—original draft preparation, J.Z.; writing—review and editing, H.S. and Y.L.; project administration, H.S. and Q.W.; funding acquisition, J.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Research Project of Tianjin Education Commission, grant number 2021KJ114.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are not available from the authors.

References

  1. Barba-Ostria, C.; Carrera-Pacheco, S.E.; Gonzalez-Pastor, R.; Heredia-Moya, J.; Mayorga-Ramos, A.; Rodríguez-Pólit, C.; Zúñiga-Miranda, J.; Arias-Almeida, B.; Guamán, L.P. Evaluation of Biological Activity of Natural Compounds: Current Trends and Methods. Molecules 2022, 27, 4490. [Google Scholar] [CrossRef] [PubMed]
  2. Clardy, J.; Walsh, C. Lessons from natural molecules. Nature 2004, 432, 829–837. [Google Scholar] [CrossRef]
  3. Patridge, E.; Gareiss, P.; Kinch, M.S.; Hoyer, D. An analysis of FDA-approved drugs: Natural products and their derivatives. Drug Discov. Today 2016, 21, 204–207. [Google Scholar] [CrossRef]
  4. Wang, S.; Dong, G.; Sheng, C. Structural Simplification of Natural Products. Chem. Rev. 2019, 119, 4180–4220. [Google Scholar] [CrossRef]
  5. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod. 2020, 83, 770–803. [Google Scholar] [CrossRef] [Green Version]
  6. Lin, H.-C.; Chiou, G.; Chooi, Y.-H.; McMahon, T.C.; Xu, W.; Garg, N.K.; Tang, Y. Elucidation of the Concise Biosynthetic Pathway of the Communesin Indole Alkaloids. Angew. Chem. Int. Ed. 2015, 54, 3004–3007. [Google Scholar] [CrossRef]
  7. Appelt, C.; Schrey, A.K.; Arvid Söderhäll, J.; Schmieder, P. Design of antimicrobial compounds based on peptide structures. Bioorg. Med. Chem. Lett. 2007, 17, 2334–2337. [Google Scholar] [CrossRef]
  8. Huang, Y.Q.; Liu, Y.X.; Liu, Y.X.; Song, H.J.; Wang, Q.M. C ring may be dispensable for b-carboline: Design, synthesis, and bioactivities evaluation of tryptophan analog derivatives based on the biosynthesis of b-carboline alkaloids. Bioorg. Med. Chem. 2016, 24, 462–473. [Google Scholar] [CrossRef]
  9. Chung, H.S.; Hon, P.M.; Lin, G.; But, P.P.H.; Dong, H. Antitussive activity of Stemona alkaloids from Stemona tuberosa. Planta Med. 2003, 69, 914–920. [Google Scholar]
  10. Gozler, T.; Gozler, B.; Weiss, I.; Freyer, A.J.; Shamma, M. (+)-Turkiyenine: An unusual extension of the biogenetic sequence for the isoquinoline alkaloids. J. Am. Chem. Soc. 1984, 106, 6101–6102. [Google Scholar] [CrossRef]
  11. Shah, J.H.; Hindupur, R.M.; Pati, H.N. Pharmacological and Biological Activities of Benzazepines: An Overview. Curr. Bioact. Compd. 2015, 11, 170–188. [Google Scholar] [CrossRef]
  12. Iwasa, K.; Kamigauchi, M.; Takao, N. Biotransformation of the Protoberberines into Benzindanoazepine- and Spirobenzyli-soquinoline-Type Alkaloids by Tissue Cultures of Several Corydalis Species. J. Nat. Prod. 1988, 51, 1232–1235. [Google Scholar] [CrossRef]
  13. Huang, J.; Shi, Q.; Choudhry, N.; Li, H.M.; Yang, C.L.; Kalashova, J.; Yan, Z.Q.; Li, J.H.; Reddy, M.C.; Gopala, S.G.; et al. Discovery and Optimization of Seven-Membered Lactam-Based Com-pounds to Phenocopy the Inhibition of the Aurora Kinase B. ACS Med. Chem. Lett. 2022, 13, 1091–1098. [Google Scholar] [CrossRef]
  14. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D.W.; Gussio, R.; Sausville, E.A.; Meijer, A.L.; Kunick, C. Paullones, a Series of Cyclin-Dependent Kinase Inhibitors: Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity. J. Med. Chem. 1999, 42, 2909–2919. [Google Scholar] [CrossRef]
  15. Egert-Schmidt, A.M.; Dreher, J.; Dunkel, U.; Kohfeld, S.; Preu, L.; Weber, H.; Ehlert, J.E.; Mutschler, B.; Totzke, F.; Schächtele, C.; et al. Identification of 2-Anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemo-types by Structure-Based Lead Generation. J. Med. Chem. 2010, 53, 2433–2442. [Google Scholar] [CrossRef] [PubMed]
  16. Arya, K.; Dandia, A. The expedient synthesis of 1,5-benzothiazepines as a family of cytotoxic drugs. Bioorganic Med. Chem. Lett. 2008, 18, 114–119. [Google Scholar] [CrossRef]
  17. Ha, S.K.; Shobha, D.; Moon, E.; Chari, M.A.; Mukkanti, K.; Kim, S.H.; Ahn, K.H.; Kim, S.Y. Anti-neuroinflammatory ac-tivity of 1,5-benzodiazepine derivatives. Bioorg. Med. Chem. Lett. 2010, 20, 3969–3971. [Google Scholar] [CrossRef]
  18. Demchenko, S.; Lesyk, R.; Yadlovskyi, O.; Zuegg, J.; Elliott, A.G.; Drapak, I.; Fedchenkova, Y.; Suvorova, Z.; Demchenko, A. Synthesis, Antibacterial and Antifungal Activity of New 3-Aryl-5H-pyrrolo[1,2-a]imidazole and 5H-Imidazo[1,2-a]azepine Quaternary Salts. Molecules 2021, 26, 253. [Google Scholar] [CrossRef] [PubMed]
  19. Thota, S.; Rodrigues, D.A.; Pinheiro, P.S.M.; Lima, L.M.; Fraga, C.A.M.; Barreiro, E.J.B. N-Acylhydrazones as drugs. Bioorg. Med. Chem. Lett. 2018, 28, 2797–2806. [Google Scholar] [CrossRef] [PubMed]
  20. Oliveira, F.A.; Pinto, A.C.S.; Duarte, C.L.; Taranto, A.G.; Junior, E.L.; Cordeiro, C.F.; Carvalho, D.T.; Varotti, F.P.; Fonseca, A.L. Evaluation of antiplasmodial activity in silico and in vitro of N-acylhydrazone derivatives. BMC Chem. 2022, 16, 1–13. [Google Scholar] [CrossRef]
  21. Gao, H.; Li, J.Q.; Kang, P.W.; Chigan, J.Z.; Wang, H.; Liu, L.; Xu, Y.S.; Zhai, L.; Yang, K.W. N-acylhydrazones confer in-hibitory efficacy against New Delhi metallo-β-lactamase-1. Bioorg. Chem. 2021, 114, 105138. [Google Scholar] [CrossRef] [PubMed]
  22. Haranahalli, K.; Lazzarini, C.; Sun, Y.; Zambito, J.; Pathiranage, S.; McCarthy, J.B.; Mallamo, J.; Del Poeta, M.; Ojima, I. SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents. J. Med. Chem. 2019, 62, 8249–8273. [Google Scholar] [CrossRef] [PubMed]
  23. Fraga, C.A.M.; Barreiro, E.J. Medicinal chemistry of N-acylhydrazones: New lead-compounds of analgesic, antiinflamma-tory and antithrombotic drugs. Curr. Med. Chem. 2006, 13, 167–198. [Google Scholar] [CrossRef]
  24. Liu, Y.X.; Song, H.J.; Huang, Y.Q.; Li, J.R.; Zhao, S.; Song, Y.C.; Yang, P.W.; Xiao, Z.X.; Liu, Y.X.; Li, Y.Q.; et al. Design, Synthesis, and Antiviral, Fungicidal, and Insecticidal Activities of Tetrahy-dro-β-carboline-3-carbohydrazide Derivatives. J. Agric. Food Chem. 2014, 62, 9987–9999. [Google Scholar] [CrossRef]
  25. Chen, L.; Xie, J.; Song, H.; Liu, Y.; Gu, Y.; Wang, L.; Wang, Q. Design, Synthesis, and Biological Activities of Spirooxindoles Containing Acylhydrazone Fragment Derivatives Based on the Biosynthesis of Alkaloids Derived from Tryptophan. J. Agric. Food Chem. 2016, 64, 6508–6516. [Google Scholar] [CrossRef]
  26. Xie, J.; Xu, W.; Song, H.; Liu, Y.; Zhang, J.; Wang, Q. Synthesis and Antiviral/Fungicidal/Insecticidal Activities Study of Novel Chiral Indole Diketopiperazine Derivatives Containing Acylhydrazone Moiety. J. Agric. Food Chem. 2020, 68, 5555–5571. [Google Scholar] [CrossRef]
  27. Wang, Q.M.; Song, H.J.; Li, L.L.; Liu, Y.X.; Wang, Z.W.; Li, Y.Q. Preparation of tetrahydroazepino[4,5-b]indole-2-carbohydrazide derivatives useful as agrochemical antiviral agents, fungicides and insecticide. CN110759913 A, 12 June 2020. [Google Scholar]
  28. Wang, K.; Su, B.; Wang, Z.; Wu, M.; Li, Z.; Hu, Y.; Fan, Z.; Mi, N.; Wang, Q. Synthesis and Antiviral Activities of Phenanthroindolizidine Alkaloids and Their Derivatives. J. Agric. Food Chem. 2009, 58, 2703–2709. [Google Scholar] [CrossRef]
  29. Zhao, H.P.; Liu, Y.X.; Cui, Z.P.; Beattie, D.; Gu, Y.C.; Wang, Q.M. Design, synthesis, and biological activities of arylme-thylamine substituted chlorotriazine and methylthiotriazine compounds. J. Agric. Food Chem. 2011, 59, 11711–11717. [Google Scholar] [CrossRef]
  30. Ni, W.; Li, C.; Liu, Y.; Song, H.; Wang, L.; Song, H.; Wang, Q. Various Bioactivity and Relationship of Structure–Activity of Matrine Analogues. J. Agric. Food Chem. 2017, 65, 2039–2047. [Google Scholar] [CrossRef]
Molecules 27 06700 g001 550
Figure 1. Natural products and pharmaceuticals containing azepine structures.
Figure 1. Natural products and pharmaceuticals containing azepine structures.
Molecules 27 06700 g001
Molecules 27 06700 g002 550
Figure 2. Design of target compounds.
Figure 2. Design of target compounds.
Molecules 27 06700 g002
Molecules 27 06700 sch001 550
Scheme 1. Synthesis of 5a−5c.
Scheme 1. Synthesis of 5a−5c.
Molecules 27 06700 sch001
Molecules 27 06700 sch002 550
Scheme 2. Synthesis of 6a−6c.
Scheme 2. Synthesis of 6a−6c.
Molecules 27 06700 sch002
Molecules 27 06700 sch003 550
Scheme 3. Synthesis of 6d−6aa.
Scheme 3. Synthesis of 6d−6aa.
Molecules 27 06700 sch003
Table
Table 1. In vivo anti-TMV activity of synthesized compounds 5a−5c, 6a−6aa 1.
Table 1. In vivo anti-TMV activity of synthesized compounds 5a−5c, 6a−6aa 1.
Compd.Concn. (µg/mL)Inhibition Rate (%)
Inactivation
Effect (%)		Curative
Effect (%)		Protection
Effect (%)
5a50044 ± 336 ± 242 ± 1
10010 ± 14 ± 114 ± 1
5b50050 ± 246 ± 443 ± 3
10020 ± 216 ± 119 ± 1
5c50055 ± 249 ± 350 ± 3
10022 ± 120 ± 126 ± 1
6a50052 ± 154 ± 347 ± 2
10016 ± 223 ± 118 ± 2
6b50035 ± 2
6c50033 ± 1
6d50041 ± 236 ± 238 ± 2
10016 ± 15 ± 28 ± 1
6e50046 ± 247 ± 337 ± 2
10010 ± 116 ± 112 ± 3
6f50040 ± 235 ± 244 ± 1
10015 ± 16 ± 110 ± 1
6g50049 ± 143 ± 450 ± 3
10021 ± 114 ± 117 ± 1
6h50054 ± 148 ± 245 ± 4
10023 ± 110 ± 420 ± 1
6i50040 ± 3
6j50036 ± 1
6k50042 ± 345 ± 246 ± 1
1009 ± 115 ± 112 ± 1
6l50034 ± 1
6m50047 ± 249 ± 241 ± 3
10014 ± 19 ± 313 ± 1
6n50051 ± 442 ± 138 ± 3
1008 ± 211 ± 117 ± 1
6o50044 ± 143 ± 239 ± 1
1007 ± 412 ± 16 ± 1
6p50037 ± 1
6q50038 ± 5
6r50032 ± 1
6s50040 ± 139 ± 143 ± 4
10011 ± 113 ± 18 ± 1
6t50052 ± 250 ± 246 ± 1
10018 ± 119 ± 111 ± 1
6u50039 ± 3
6v50056 ± 246 ± 449 ± 3
10022 ± 119 ± 215 ± 1
6w50035 ± 2
6x50038 ± 3
6y50052 ± 354 ± 148 ± 1
10021 ± 124 ± 116 ± 1
6z50037 ± 3
6aa50037 ± 3
ningnanmycin50057 ± 255 ± 358 ± 1
10028 ± 126 ± 127 ± 2
rabvirin50040 ± 137 ± 139 ± 2
10012 ± 111 ± 115 ± 1
1 When the inactivation effect of a compound was less than 40%, its protection and curative effects were not determined.
Table
Table 2. Larvicidal activity of compounds 5a−5c, 6a−6aa against Plutella xylostella.
Table 2. Larvicidal activity of compounds 5a−5c, 6a−6aa against Plutella xylostella.
CompdLarvicidal Activity at Various Concentrations (mg/L)
600200100502510
5a90 ± 050 ± 00
5b10010060 ± 030 ± 0
5c10010076 ± 640 ± 0
6a50 ± 0
6b90 ± 060 ± 030 ± 0
6c40 ± 0
6d70 ± 050 ± 0
6e60 ± 040 ± 0
6f70 ± 040 ± 0
6g10080 ± 040 ± 0
6h10070 ± 040 ± 0
6i70 ± 030 ± 0
6j60 ± 030 ± 0
6k10010080 ± 060 ± 040 ± 0
6l10070 ± 030 ± 10
6m10010080 ± 076 ± 640 ± 0
6n90 ± 050 ± 0
6o70 ± 030 ± 0
6p76 ± 630 ± 0
6q40 ± 0
6r0
6s70 ± 050 ± 0
6t50 ± 0
6u90 ± 070 ± 040 ± 0
6v10010050 ± 0
6w50 ± 0
6x76 ± 643 ± 6
6y10070 ± 040 ± 0
6z10010086 ± 670 ± 056 ± 630 ± 0
6aa60 ± 020 ± 0
Table
Table 3. LC50 value of 6z against Plutella xylostella.
Table 3. LC50 value of 6z against Plutella xylostella.
Compd.y = ax + bLC50 (mg/L)Correlation Coefficient
6zy = 1.5974x + 2.879921.20.9989
Table
Table 4. Fungicidal activity of compounds 5a−5c, 6a−6aa against fourteen kinds of phytopathogens 1.
Table 4. Fungicidal activity of compounds 5a−5c, 6a−6aa against fourteen kinds of phytopathogens 1.
Compd.Inhibition Rate (% at 50 mg/L)
A.S.F.G.P.I.P.C.S.S.B.C.R.S.F.C.C.H.P.P.R.C.B.M.C.O.F.M.
5a56 ± 133 ± 151 ± 160 ± 269 ± 131 ± 128 ± 159 ± 183 ± 142 ± 290 ± 151 ± 150 ± 184 ± 1
5b58 ± 152 ± 251 ± 165 ± 166 ± 147 ± 135 ± 139 ± 141 ± 327 ± 152 ± 136 ± 250 ± 152 ± 1
5c45 ± 245 ± 274 ± 275 ± 276 ± 249 ± 266 ± 240 ± 252 ± 231 ± 260 ± 239 ± 147 ± 156 ± 1
6a33 ± 132 ± 159 ± 140 ± 042 ± 138 ± 133 ± 133 ± 146 ± 120 ± 144 ± 123 ± 140 ± 166 ± 2
6b47 ± 158 ± 139 ± 131 ± 157 ± 138 ± 128 ± 136 ± 156 ± 122 ± 153 ± 150 ± 153 ± 165 ± 1
6c33 ± 156 ± 135 ± 135 ± 142 ± 125 ± 132 ± 141 ± 136 ± 120 ± 050 ± 133 ± 157 ± 161 ± 1
6d52 ± 145 ± 143 ± 140 ± 149 ± 129 ± 137 ± 143 ± 162 ± 144 ± 192 ± 136 ± 147 ± 170 ± 0
6e58 ± 144 ± 135 ± 150 ± 032 ± 134 ± 135 ± 139 ± 136 ± 120 ± 135 ± 161 ± 147 ± 166 ± 1
6f50 ± 045 ± 130 ± 032 ± 142 ± 138 ± 139 ± 130 ± 052 ± 120 ± 157 ± 129 ± 150 ± 052 ± 1
6g43 ± 147 ± 328 ± 135 ± 155 ± 129 ± 135 ± 136 ± 136 ± 120 ± 153 ± 136 ± 157 ± 156 ± 1
6h33 ± 126 ± 143 ± 137 ± 132 ± 138 ± 128 ± 123 ± 142 ± 137 ± 164 ± 163 ± 150 ± 161 ± 1
6i39 ± 134 ± 131 ± 130 ± 027 ± 241 ± 132 ± 136 ± 146 ± 130 ± 170 ± 026 ± 140 ± 059 ± 1
6j45 ± 126 ± 235 ± 131 ± 142 ± 138 ± 130 ± 033 ± 146 ± 120 ± 153 ± 123 ± 150 ± 166 ± 1
6k47 ± 226 ± 128 ± 130 ± 154 ± 138 ± 128 ± 135 ± 173 ± 227 ± 153 ± 136 ± 150 ± 070 ± 1
6l59 ± 130 ± 137 ± 135 ± 130 ± 135 ± 131 ± 136 ± 178 ± 120 ± 146 ± 229 ± 140 ± 167 ± 1
6m33 ± 134 ± 135 ± 136 ± 137 ± 129 ± 139 ± 152 ± 146 ± 144 ± 110042 ± 150 ± 171 ± 1
6n45 ± 126 ± 131 ± 140 ± 135 ± 134 ± 242 ± 136 ± 149 ± 137 ± 157 ± 136 ± 157 ± 161 ± 1
6o54 ± 124 ± 135 ± 230 ± 136 ± 134 ± 128 ± 139 ± 146 ± 157 ± 159 ± 143 ± 160 ± 056 ± 1
6p58 ± 333 ± 128 ± 125 ± 132 ± 131 ± 125 ± 143 ± 167 ± 359 ± 155 ± 145 ± 147 ± 166 ± 1
6q53 ± 138 ± 138 ± 135 ± 140 ± 029 ± 151 ± 130 ± 036 ± 132 ± 157 ± 133 ± 157 ± 147 ± 1
6r72 ± 145 ± 274 ± 224 ± 191 ± 138 ± 170 ± 030 ± 067 ± 120 ± 166 ± 157 ± 153 ± 256 ± 1
6s70 ± 035 ± 143 ± 137 ± 127 ± 134 ± 134 ± 136 ± 157 ± 125 ± 150 ± 029 ± 160 ± 156 ± 1
6t45 ± 126 ± 141 ± 130 ± 142 ± 129 ± 128 ± 246 ± 194 ± 127 ± 198 ± 133 ± 157 ± 1100
6u33 ± 123 ± 151 ± 140 ± 157 ± 259 ± 239 ± 136 ± 141 ± 125 ± 159 ± 126 ± 153 ± 156 ± 3
6v70 ± 070 ± 035 ± 137 ± 149 ± 329 ± 135 ± 136 ± 157 ± 127 ± 155 ± 133 ± 157 ± 166 ± 1
6w45 ± 159 ± 151 ± 142 ± 137 ± 136 ± 128 ± 136 ± 141 ± 120 ± 190 ± 036 ± 153 ± 156 ± 1
6x58 ± 145 ± 146 ± 140 ± 144 ± 129 ± 125 ± 135 ± 152 ± 132 ± 153 ± 128 ± 167 ± 152 ± 1
6y54 ± 158 ± 174 ± 150 ± 169 ± 156 ± 132 ± 136 ± 131 ± 130 ± 055 ± 139 ± 157 ± 161 ± 1
6z58 ± 158 ± 145 ± 145 ± 269 ± 156 ± 140 ± 141 ± 173 ± 120 ± 163 ± 141 ± 160 ± 156 ± 1
6aa50 ± 033 ± 166 ± 143 ± 186 ± 175 ± 135 ± 142 ± 146 ± 137 ± 163 ± 129 ± 161 ± 161 ± 1
chlorothalonil38 ± 110085 ± 190 ± 098 ± 182 ± 192 ± 171 ± 153 ± 110 ± 098 ± 156 ± 180 ± 141 ± 1
1 A.S., Alternaria solani; F.G., Fusarium graminearum; P.I., Phytophthora infestans; P.C., Phytophthora capsici; S.S., Sclerotinia sclerotiorum; B.C., Botrytis cinerea; R.S., Rhizoctonia solani; F.C., Fusarium oxysporum sp. cucumeris; C.H., Cercospora arachidicola Hori; P.P., Physalospora piricola; R.C., Rhizoctonia cerealis; B.M., Bipolaris maydis; C.O., Colletotrichum orbiculare; F.M., Fusarium moniliforme.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Zhang, J.; Yang, R.; Li, L.; Liu, J.; Liu, Y.; Song, H.; Wang, Q. Design, Synthesis, and Bioactivity Study of Novel Tryptophan Derivatives Containing Azepine and Acylhydrazone Moieties. Molecules 2022, 27, 6700. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27196700

AMA Style

Zhang J, Yang R, Li L, Liu J, Liu Y, Song H, Wang Q. Design, Synthesis, and Bioactivity Study of Novel Tryptophan Derivatives Containing Azepine and Acylhydrazone Moieties. Molecules. 2022; 27(19):6700. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27196700

Chicago/Turabian Style

Zhang, Jingjing, Rongxin Yang, Lili Li, Jianhua Liu, Yuxiu Liu, Hongjian Song, and Qingmin Wang. 2022. "Design, Synthesis, and Bioactivity Study of Novel Tryptophan Derivatives Containing Azepine and Acylhydrazone Moieties" Molecules 27, no. 19: 6700. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27196700

Article Metrics

Back to TopTop